# Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

> **NCT05556720** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Monash University** · enrollment: 960 (estimated)

## Conditions studied

- HIV
- Organ Transplantation
- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia
- Multiple Myeloma
- COVID-19 Vaccines

## Interventions

- **BIOLOGICAL:** Pfizer Bivalent COVID-19 Vaccine
- **BIOLOGICAL:** Moderna Bivalent mRNA vaccine

## Key facts

- **NCT ID:** NCT05556720
- **Lead sponsor:** Monash University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 960 (ESTIMATED)
- **Last updated:** 2025-10-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05556720

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05556720, "Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05556720. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*